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ABSTRACT 
Objective:  To determine the seroprevalence of hepatitis B surface antigen (HBsAg) 
and possible risk factors in pregnant women.
Design: A cross –sectional serological survey of women attending antenatal clinics.
Setting: Five antenatal clinics in Aba, South Eastern Nigeria.
Subjects: Eight hundred and ten consecutive and consenting antenatal clinic attendees 
over the  period 15 June- 15 November 2010.
Main Outcome measures: For each pregnant woman, the medical and sociodemographic 
data  were documented. Hepatitis B surface antigen seropositivity determined.
Results: Twenty two (2.7%)  of the 810 subjects were found to be HBsAg seropositive 
and asymptomatic. Maternal age, parity, educational level attained, marital status, 
history of blood transfusion, intravenous drug use, tattooing, jaundice in the past and 
Human Immunodeficiency Virus seropositivity did not show any association with 
HBsAg sseropositivity.
Conclusion: HBsAg seropositive women in the study were asymptomatic and showed 
no association with the medical and sociodemographic characteristics examined. These 
findings affirm the recommendation for universal HBsAg screening in pregnancy 
and imply that screening on the basis of the presence of risk factors alone may be 
insufficient.
INTRODUCTION
Human infection with Hepatitis B virus (HBV) is a 
global health problem (1). Approximately 400 million 
people are chronically infected with HBV worldwide 
(2) and almost half have acquired their infections 
either through mother to infant transfusion or in the 
early childhood, especially in countries where HBV 
has intermediate to high prevalence (3). This is due 
to the high rates of  HBsAg positivity in women of 
child-bearing age in these parts of the world and the 
transmission of infection from these women to their 
newborns (4).
 The principal screening test for detecting 
maternal HBV infection is the serological identification 
of HBsAg. The knowledge of the seroprevalence of 
HBsAg and possible medical and sociodemographic 
risk factors in pregnant women will assist in 
developing a strategy to inform and educate the 
public regarding HBV.
 Diagnosis of HBV in the context of pregnancy-
specific screening opens the opportunity for 
individuals who might otherwise have not ever been 
tested to receive appropriate care. Further, other 
benefits of detection of infected pregnant women 
include the identification not only of infants who 
require prophylaxis but also of sexual and household 
contacts of the infected pregnant women who will 
benefit from testing, counseling ,vaccination or 
therapy if indicated. Hence, the need for this study.
MATERIALS AND METHODS
This was a cross –sectional survey involving 810 
consecutive and consenting antenatal clinic attendees 
at five antenatal clinics in Aba, South-Eastern Nigeria 
over the period 15 June – 15 November, 2010.
 A structured pre-tested questionnaire 
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administered by research assistants was used to collect 
and record data on the medical and sociodemographic 
characteristics of the subjects.
 Blood samples were collected from the consenting 
antenatal clinic attendees and tested for HBsAg using 
rapid test Elisa kits (Acon laboratories, USA).
 Data analysis included descriptive statistics 
for demographic  data and calculation of the 
seroprevalence of HBsAg  in the pregnant women. 
Association of HBsAg seropositivity with potential 
medical and socidemographic risk factors was 
assessed. Statistical analysis were performed using 
Epi-info version 6 statistical package. P < 0.05 was 
considered significant. Ethical approval for the study 
was obtained from the research and ethical committee 
of Abia State University Teaching Hospital, Aba.
RESULTS
Table 1 shows  the sociodemographic characteristics 
of the antenatal attendees studied.
A total of  810 antenatal attendees took part in this 
study. The modal age of the women was 24     years 
and the average age 26.5 years. The majority of the 
women were multiparous and of the Igbo ethnic 
group in Nigeria.
Table 1
Medical and socio-demographic characteristics of participants















Single/ Divorced/ Widowed 0 0




Self and partner intravenous drug use
Yes 0 0
No 810 100
Ever received blood transfusion
Yes 44 5.4
No 766 94.6
Ever been jaundiced in the past? 
Yes 12 1.5
No 798 98.5
HIV  Screening test result
Positive 8 0.9
Negative 802 99.0 
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Table 2 shows the relationship between maternal 
variables and HBsAg seropositivity. Twenty two 
(2.7%) of the 810 subjects were found to be HBsAg 
seropositive. Maternal age, parity, educational level 
attained, marital status, history of having received 
blood transfusion in the past, tattooing or jaundice 
in the past and Human Immunodeficiency virus 
(HIV) positivity did not show any association with 
HBsAg seropositivity.
Table 2
Maternal socio-demographic characteristics by maternal Hepatitis B positivity
Variables Hepatitis B Negative Hepatitis B positive
 No. = 788(%) No. = 22(%)
Maternal age
 <19                   5 100 0 0
 20-29 423 96.8 14 3.2
 >30 360 97.8 8 2.2
   X2 = 0.94; P > 0.05
Parity
 Nullipara 278 97.2 8 2.8
 Primipara 180 97.2 5 2.7
 Multipara 330 97.3 9 2.7
   X2 = 0.01; P > 0.99
Maternal education 
 Primary 7 100 0 0
     Secondary             310 97.8 7 2.2
     Tertiary 471 96.9 15 3.1
   X2 = 0.76; P > 0.68
Undergoing STI treatment other than HIV/AIDS
 Yes 28 93.3 2 6.7
     No 760 97.4 20 2.6
   X2 = 0.62; P > 0.43
Ever received blood transfusion
 Yes 44 100 0 0
    No 744 97.1 22 0.1
   X2  =  0.44; P > 0.5
Ever been jaundiced in the past
 Yes 12 100 0 0
 No 776 97.2 22 2.8
  X2 =  0.10; P > 0.75
HIV screening test result
 Positive 7 87.5 1 12.5
 Negative 781 97.4 21 2.6
   X2  =  0.38; P > 0.53
The prevalence of maternal HBsAg seropositivity is  2.7%. 
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 DISCUSSION
The sero-prevalence of HBsAg in pregnant women 
was found to be 2.7% in this study. This is within 
the range of 2 and  12%  found by  other authors in 
Nigeria but lower than the seroprevalence of 11.0% in 
Makurdi, North Central Nigeria, 11.6% in Maiduguri, 
North Eastern Nigeria and 13.8% in Lagos, Western 
Nigeria (5,6,7). The seroprevalence found in our study 
is also lower than that of greater than 8% reported for 
Africa, Asia and the western pacific but higher than 
the less than 2% obtained in Western Europe, North 
America, Japan and Australia (8).
 The wide variations in the seroprevalence of 
HBsAg in pregnant women from the literature may be 
due to geographical variation, differences in cultural 
practices, sexual behavior, practices and differences 
in the test methods employed to detect HBV infection 
(9).
 HBsAg seropositivity in this study showed 
no association with known selected medical and 
sociodemographic risk factors examined. Further, 
all the HBsAg seropositive pregnant women in our 
study were asymptomatic and unaware of their 
infection. There can be two approaches to screening 
for HBsAg during pregnancy namely, universal or 
at risk. Universal screening approach means that 
all pregnant women are screened for HBV infection 
whereas the at risk approach relies on the historical 
“risk factors” (eg intravenous drug use, promiscuous 
heterosexuals, commercial sex workers, sex partners 
of HBsAg –positive persons) to determine whom to 
screen (10). In some parts of the world, generally 
there is no consistent policy with respect to testing 
of women with HBV infection during pregnancy 
and many countries rely on “historical risk factors” 
to determine the indications for screening.
 Thus, universal screening as opposed to risk 
factor based screening of all pregnant women for 
HBV is justified in our setting  since risk factor-based 
screening results in missing as many as 50% HBsAg 
seropositive individuals in some populations  as 
shown by a study from Denmark (11). Furthermore the 
perinatal screening allows for identification of infants 
requiring immunoprophylaxis with HBV vaccine and 
hepatitis B immune globin (HBIG), antiviral treatment 
of pregnant carriers if indicated, and counseling of 
sexual and household contacts (12).
 Strengths of our study include the fairly large 
sample size. Limitations include possible selection 
bias as the participants were volunteers and not 
selected randomly.
In conclusion, our study showed that HBsAg 
seropositive pregnant women were asymptomatic 
and showed no association with known selected 
medical and sociodemographic risk factors examined. 
These findings affirm the recommendation for 
universal HBsAg screening in pregnancy and imply 
that screening on the basis of the presence of risk 
factors alone may not be sufficient  in our setting. 
It is recommended that studies with much larger 
sample sizes in Aba and other communities in Nigeria 
and the rest of Africa are warranted to confirm these 
findings. There is need for a national HBsAg screening 
programme in pregnancy.
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